Mounjaro 2.5 mg Injection Pen

Description

The Mounjaro 2.5 mg Injection Pen is the starting dose in the tirzepatide treatment plan. This once-weekly injectable helps adults with type 2 diabetes or obesity begin dual GLP-1 and GIP receptor therapy, enhancing insulin function, reducing appetite, and promoting steady metabolic improvements.

Mounjaro’s unique dual-hormone mechanism makes it one of the most effective and well-tolerated options for long-term weight and glucose management.

Key Features:

• Contains 2.5 mg tirzepatide per pen (starting dose)

• Combines GLP-1 and GIP receptor activity

• Reduces blood glucose and supports appetite control

• Once-weekly injection for convenience

• Backed by extensive clinical trials (FDA Press Release)

Usage Instructions:

• Inject once weekly, on the same day each week

• Can be injected into the abdomen, thigh, or upper arm

• Rotate injection sites to prevent irritation

• Begin with 2.5 mg for the first 4 weeks before increasing to 5 mg as prescribed

• Use exactly as directed by your healthcare provider

Mounjaro 2.5 mg Injection Pen Side Effects:

Mild nausea or digestive discomfort may occur during the first weeks of treatment. These typically subside as the body adjusts. For full guidance, review the Mounjaro Medication Guide (FDA).

Storage Instructions:

• Store refrigerated between 36°F–46°F (2°C–8°C)

• Keep in original carton to protect from light

• Do not freeze or expose to heat